Searched for
DOMESTIC PHARMACEUTICAL REVENUE
Natco Pharma Q1 profit falls 57 pc to Rs 206.5 crNatco Pharma has reported a stark profit decline in the first quarter, largely driven by reduced sales of its leading cancer drug, lenalido...- FIIs dumped nearly Rs 1 lakh crore worth of these 10 stocks but 8 defied the selloffForeign investors sold nearly Rs 1 lakh crore from ten Indian stocks. Eight of these companies saw their stock prices increase despite the ...
- Q1 Earnings Scorecard: Strong demand drives revenue, input costs hit profitsSustained market demand led to impressive revenue growth in the automotive and consumer goods sectors. In contrast, while the banking secto...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Warburg set to buy Seacod-maker Universal NutriScience for Rs 2800 croreWill be 4th acquisition for the US private equity giant in India’s healthsector in four months. Kedaara to make 5x rupee returns on exit.
- These large and mid-cap stocks can give more than 20% return in 1 year, according to analystsWhenever there is a correction or volatility, just ask one question: Is it an opportunity, or should one be wary? We are raising this issue...
- Time to increase the risk quotient? Maybe, but selectively: 5 largecaps from different sectors with upside potential of up to 30%When a market starts rising and buying makes a comeback, something happens to a large majority of investors. They get restless. The safe, m...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- India ready for a premium wealth show while US missiles rattle the worldIndia's festive shopping season is set to highlight the country's premiumisation boom despite global uncertainty triggered by the US-Iran w...
- Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5%Sun Pharma Q1 Results: Sun Pharma reported a 27% YoY rise in Q1 net profit to Rs 2,895 crore, while revenue grew 10% to Rs 15,300 crore, dr...
- Why Axis Mutual Fund is asking investors to look at largecaps as wellFollowing the sharp re-rating in small- and midcaps, Axis Mutual Fund has urged investors to revisit largecaps, saying their valuations hav...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Sunil Singhania adds two new stocks in Q1 that have risen up to 93% in 2026. Do you own any?Sunil Singhania's Abakkus Asset Management added two new stocks and increased holdings. The firm acquired stakes in Afcom Holdings and TTK ...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPCMarkets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...
- Cipla expects sequential recovery in North America on new product launches despite tariff uncertaintyCipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...
- Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...
- Domestic formulations, chronic therapies to drive Pharma Q1; US generics remain dragThe healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
Load More
